magrolimab,azacitidine
gilead sciences
['mds', 'magrolimab']
congress #asco22 | david sallman discusses magrolimab + aza for hr #mds in a phase ib study. n=95. duration of cr, duration of or, &amp; pfs were 11.1, 9.8, &amp; 11.6 mos, respectively. cr rate was 32.6% and orr was 74.7% with similar rates between tp53 wt and mut #mdssm 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm